Novus Therapeutics, Inc. (NVUS) financial statements (2021 and earlier)

Company profile

Business Address 19900 MACARTHUR BLVD.
IRVINE, CA 92612
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments911149131619
Cash and cash equivalents911149131619
Receivables0111   
Prepaid expense1110112
Other current assets0000100
Other undisclosed current assets0      
Total current assets:10121510141721
Noncurrent Assets
Operating lease, right-of-use asset00  
Property, plant and equipment0000000
Intangible assets, net (including goodwill) 222222
Goodwill 222222
Other noncurrent assets111111 
Other undisclosed noncurrent assets  00   
Total noncurrent assets:1333332
TOTAL ASSETS:11151813172023
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1112211
Accounts payable0010111
Accrued liabilities0000000
Employee-related liabilities0101100
Debt00     
Postemployment benefits liability     00
Other undisclosed current liabilities0011   
Total current liabilities:1223211
Noncurrent Liabilities
Long-term debt and lease obligation00     
Operating lease, liability00  
Other undisclosed noncurrent liabilities  00   
Total noncurrent liabilities:0000   
Other undisclosed liabilities    100
Total liabilities:1224321
Stockholders' equity
Stockholders' equity attributable to parent9131610141822
Common stock0000000
Additional paid in capital67676756565555
Accumulated deficit(58)(53)(51)(46)(42)(37)(34)
Total stockholders' equity:9131610141822
TOTAL LIABILITIES AND EQUITY:11151813172023

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Operating expenses(4)(3)(4)(5)(5)(3)(3)
Operating loss:(4)(3)(4)(5)(5)(3)(3)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
00(0)(0)00 
Net loss available to common stockholders, diluted:(4)(3)(4)(5)(5)(3)(3)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(4)(3)(4)(5)(5)(3)(3)
Comprehensive loss, net of tax, attributable to parent:(4)(3)(4)(5)(5)(3)(3)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: